The list encompasses a diverse portfolio of patent rights, including rights to screening targets, such as receptors and response elements, as well as novel screens and modulators of several of the receptors. The cases where Ligand has retained U.S. rights have been italicized.
Later technologies are available on a worldwide basis.
Also, several of the later technologies will necessitate a confidentiality agreement to allow full review. Salk Technology Salk Ref. Ligand has retained US rights Salk Technology Salk Ref. Available Ecd gene switch for protein production, gene therapy etc. Ligand has retained US rights Salk Technology Salk Ref.